Bill · S. 1637· Senate(119-S-1637)
MVP Act
- Introduced
- 5/7/2025
- Last activity
- 5/7/2025 — Read twice and referred to the Committee on Finance.
- Sponsored by
- Markwayne Mullin
- Cosponsors
- - 1 - 1
- Introduced
- In Committee
What this bill would do
The "Medicaid VBPs for Patients Act" (or "MVP Act") aims to codify value-based purchasing arrangements within the Medicaid program. It updates how drug prices are reported and calculated, specifically allowing for multiple best price points for single drugs if offered to all States. The bill provides guidance for these arrangements regarding inpatient drugs and creates an exception under the antikickback statute for certain payments triggered by patient outcomes. Finally, it mandates a GAO study to evaluate how these arrangements affect patient access, outcomes, and healthcare costs.
Yes· 3 of 18
Would households on low incomes be better off under this?+6
Improves access to high-cost transformative therapies for Medicaid recipients.
Does this make health care easier to get in general?+5
Aims to facilitate access to transformative therapies and gene therapies for rare diseases.
Would people with disabilities be better off under this?+4
Facilitates access to rare disease therapies and transformative treatments.
The opposite
No question was scored the opposite.
Who it would affect, and how
Potential Positive Impacts for People
-
Improved Access to Therapies: Section 6(a)(1)(A) directs a study on how these arrangements facilitate access to transformative therapies, including gene therapies for rare diseases.
-
Reducing Disparities: Section 6(a)(1)(B) focuses on mitigating socioeconomic disparities by requiring State Medicaid programs to have access to the same pricing structures available in the commercial market.
-
Outcome-Based Accountability: Section 2(b)(1)(A)(iv) allows for refunds, rebates, or payment reductions to manufacturers if a patient fails to achieve specific outcomes or measures defined in the arrangement.
-
Patient Mobility: Section 4 provides guidance for States to enter agreements allowing funds to transfer between States, so people receiving inpatient drugs in a different State from where they reside can be treated as if they received the drug in their home State.
Potential Negative Impacts for People
-
Limited Availability: Section 2(a)(1)(D) specifies that multiple best price points are only available if the manufacturer offers the arrangement to all States, which could limit the benefit if a manufacturer does not offer it universally.
-
Price Uncertainty: Section 6(a)(1)(E) indicates a need to study the impact on drug prices for people in States that choose not to enter into these value-based purchasing arrangements.
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
- Demographic And Interest Groups
- Good For Low Income Households+6Good For People With Disabilities+4Good For African Americans+2Good For Asian Americans+2Good For Children+2Good For Hispanic Americans+2Good For Middle Aged+2Good For Native Americans+2Good For Seniors+2Good For White Americans+2Good For Young Adults+2
- Healthcare
- Improves Healthcare Access+5Reduces Prescription Drug Costs+4
- Governance And Ideology
- Improves Interstate Commerce+2Increase States Rights+1
- Economy And Finance
- Improves Fiscal Responsibility+1Reduces Government Spending+1
- Social Issues And Justice
- Improves Racial Equity+2
- 5/7/2025
- Read twice and referred to the Committee on Finance.
- 2 Cosponsors added.
- Introduced in Senate
One bill Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Maggie HassanDemocrat · New Hampshire
Tim ScottRepublican · South Carolina